Navigation Links
Investigational Urine NGAL Biomarker Shows Promise to Monitor Cyclosporine Toxicity in Cardiac Transplant Patients

CHICAGO, July 22 /PRNewswire-FirstCall/ -- Research presented at the American Association for Clinical Chemistry (AACC) annual meeting today indicates that monitoring cardiac transplant patients with the Urine NGAL assay on Abbott's ARCHITECT immunoassay analyzer may help clinicians to monitor cyclosporine-induced toxicity and adjust doses of cyclosporine drugs to prevent possible irreversible kidney damage.

In a scientific poster presented at AACC today by researchers at the University of Toronto, eleven heart transplant patients were treated with anti-rejection drug combinations and monitored with the Urine NGAL assay within twelve hours of administration. The study concluded that Urine NGAL monitoring may be able to assist in the detection of chronic cyclosporine-induced toxicity in the kidneys following heart transplant procedures.

Abbott is currently developing an assay to measure NGAL (neutrophil gelatinase-associated lipocalin) concentrations in urine for use on the company's flagship automated laboratory instrument, the ARCHITECT system. Abbott has rights to commercialize Urine NGAL for renal diagnostic applications and is expected to introduce the product in Europe in late 2009. The assay is not available in the United States. NGAL is a small, robust protein produced by the kidney tubules and appears in urine just two-to-four hours following acute kidney injury (AKI), up to 46 hours sooner than current test methods.

"Nephrologists and cardiologists are excited about the potential of Urine NGAL to detect the potential for kidney failure following cardio-thoracic surgeries," said Sudarshan Hebbar, M.D., medical director, Abbott Diagnostics.

About Abbott's Diagnostics Businesses

Abbott is a global leader in in vitro diagnostics and offers a broad range of innovative instrument systems and tests for hospitals, reference labs, molecular labs, blood banks, physician offices and clinics. With more than 69,000 institutional customers in more than 100 countries, Abbott's diagnostic products offer customers automation, convenience, bedside testing, cost effectiveness and flexibility. Abbott has helped transform the practice of medical diagnosis from an art to a science through the company's commitment to improving patient care and lowering costs. The history of Abbott is filled with examples of first-of-a-kind diagnostic products and significant technological and research advancements.

About Abbott

Abbott (NYSE: ABT) is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs more than 72,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available on the company's Web site at

ARCHITECT is a trademark of Abbott Laboratories.

Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. New Phase 3 Data Continue to Indicate that Wyeths Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease
2. FDA Accepts Investigational New Drug (IND) Application for Tigris Pharmaceuticals GGTI-2418
3. Medarex Announces Allowance of Investigational New Drug Application for Companys First Antibody-Drug Conjugate, MDX-1203
4. International Robotic Urology Symposium Reports on Benefits of Cooling During Robotic-Assisted Prostate Surgery and Introduces InnerCools New Investigational UroCool System
5. Phase 3 Data Demonstrate Efficacy and Tolerability of Paliperidone Palmitate, an Investigational Long-Acting Therapy for the Treatment of Schizophrenia
6. Retrospective Analysis of Phase 3 Data Suggest Wyeths Investigational Compound Bazedoxifene/Conjugated Estrogens Comparable to Placebo on Incidence of Abnormal Mammograms
7. Lixte Biotechnology Holdings Announces Filing of a New Patent Application for Cancer Therapy Based on Targeting a Biomarker by Novel Investigational Agents
8. SGX Pharmaceuticals Submits Investigational New Drug Application for SGX393
9. U.S. Food and Drug Administration Advisory Committee Recommends Approval of Tolvaptan, an Investigational Treatment for Hyponatremia
10. Novel Investigational Regimen Combining Radiation Enhancing Agent With Ibritumomab Tiuxetan (Zevalin(R)) Produces High Rate of Complete Responses in Patients With Rituximab-Refractory Follicular Non-Hodgkins Lymphoma
11. NeurogesX Opens Investigational New Drug Application for Capsaicin Liquid Formulation NGX-1998
Post Your Comments:
(Date:6/27/2016)... , June 27, 2016  Global demand for ... percent through 2020 to $7.2 billion.  This market ... beverages, cleaning products, biofuel production, animal feed, and ... diagnostics, and biocatalysts). Food and beverages will remain ... by increasing consumption of products containing enzymes in ...
(Date:6/27/2016)... Diego, CA (PRWEB) , ... June 27, 2016 , ... ... solutions for clinical trials, announced today the Clinical Reach Virtual Patient Encounter ... their care circle with the physician and clinical trial team. , Using the CONSULT ...
(Date:6/27/2016)... , June 27, 2016   Ginkgo Bioworks , ... industrial engineering, was today awarded as one of ... of the world,s most innovative companies. Ginkgo Bioworks ... for the real world in the nutrition, health ... work directly with customers including Fortune 500 companies ...
(Date:6/24/2016)... ... 2016 , ... Researchers at the Universita Politecnica delle Marche in Ancona combed ... pleural mesothelioma. Their findings are the subject of a new article on the Surviving ... signposts in the blood, lung fluid or tissue of mesothelioma patients that can help ...
Breaking Biology Technology:
(Date:6/22/2016)... June 22, 2016   Acuant , ... verification solutions, has partnered with RightCrowd ® ... for Visitor Management, Self-Service Kiosks and Continuous ... that add functional enhancements to existing physical ... and venues with an automated ID verification ...
(Date:6/15/2016)... June 15, 2016 Transparency ... titled "Gesture Recognition Market by Application Market - Global Industry Analysis ... 2024". According to the report, the  global gesture recognition ... 2015 and is estimated to grow at a ... by 2024.  Increasing application of gesture ...
(Date:6/2/2016)... 2, 2016 The Department of Transport ... the 44 million US Dollar project, for the , ... including Personalization, Enrolment, and IT Infrastructure , to ... production and implementation of Identity Management Solutions. Numerous renowned international ... Decatur was selected for the most compliant ...
Breaking Biology News(10 mins):